HOME >> BIOLOGY >> NEWS
SFVAMC/UCSF researchers develop lead for a new Alzheimer's disease drug - a fragment of a brain growth protein

In findings that could lead to a new Alzheimer's disease drug, researchers at San Francisco Veterans Affairs Medical Center (SFVAMC) and University of California, San Francisco have isolated a protein fragment that nurtures brain cells, an effect that could prevent loss of brain function caused by the disease.

The fragment acts through the same mechanisms as its larger parent protein. However, a drug based on the fragment would be small enough to pass from the bloodstream into the brain, the researchers said.

These findings were presented today (November 8) in New Orleans at the 30th Annual meeting of the Society for Neuroscience, the world's largest neuroscience meeting.

The fragment is derived from a protein called Nerve Growth Factor (NGF), which maintains the health of many types of brain cells, including those damaged by Alzheimer's disease; it also helps strengthen the connections between cells.

But NGF can't be used as a treatment because the molecule is too large to get past the filtering mechanisms that protect the brain from bacteria and other agents in the blood that might damage it, said Frank Longo, MD, PhD, a UCSF professor and vice chair of neurology and SFVAMC chief of research.

Longo and his colleagues now have found that a much smaller portion of NGF may carry NGF's most useful functions.

"These studies offer the first demonstration that a small molecule mimicking a specific part of the NGF protein can activate the same key mechanisms in neurons that are activated by NGF, and in doing so prevent death of these neurons. Prior to this work, it was widely believed that the entire NGF protein was required to achieve its death-preventing activity," Longo said.

Other researchers had determined which sections of the NGF molecule dock to NGF receptors. Longo and his colleagues were hopeful that if they isolated these receptor-binding pieces, one of them might nurture nerve cells in the same way as the wh
'"/>

Contact: Kevin Boyd
kboyd@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
7-Nov-2000


Page: 1 2 3

Related biology news :

1. Belgian researchers explore revolutionary approach to angiogenesis
2. Award winning researchers reveal potential new role for Glivec
3. $7.5 Million grant to Yale researchers for role of viruses in cancer
4. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
5. Joslin researchers clarify mechanisms for beta-cell formation
6. Virginia Tech researchers to release findings on Smith River Project
7. Molecular motor myosin VI moves hand over hand, researchers say
8. ASU researchers demonstrate new technique that improves the power of atomic force micrscopy
9. Emory researchers map structure of anti-cancer molecule
10. Leukemia stem cells identified by Stanford researchers
11. EURYI Award given for the first time to 25 young European researchers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/3/2019)... ... 02, 2019 , ... Personalized Stem Cells, Inc (“PSC”), a human ... approved clinical trial for stem cell treatment of knee osteoarthritis . The successful enrollment ... a subsidiary of VetStem Biopharma. , PSC CEO, Michael Dale, stated, “We are proud ...
(Date:9/30/2019)... ... September 30, 2019 , ... RoosterBio ... stem/stromal cell (hMSC) biomanufacturing systems, today announced it has received patent approval ... formats (patent number AU 2015259373). This new patent adds intellectual property (IP) ...
(Date:9/25/2019)... ... September 25, 2019 , ... Deep Science Ventures (DSV), a ... world’s largest independent funder of cancer research. , Deep Science Ventures was founded to ... view of the opportunity from the start, both at the industry and biological level. ...
Breaking Biology News(10 mins):
(Date:10/10/2019)... ... 2019 , ... VirTrial today announced an alliance ... All Pratia research centers have completed VirTrial’s Virtual Trial Capable training, making them ... Trial Capable and prepared to conduct decentralized clinical trials (DCT). , The training ...
(Date:10/8/2019)... ... October 07, 2019 , ... Erchonia Corporation, the global leader ... announces that the U.S. Food and Drug Administration (FDA) has granted the company ... relief of chronic neck and shoulder pain of musculoskeletal origin. , Erchonia continues ...
(Date:10/3/2019)... ... 01, 2019 , ... Today Cereset®, the only proven non-invasive ... of its randomized research trial for individuals with persisting symptoms following mild-Traumatic Brain ... a non-invasive technology which compares tones delivered to a subject’s brain guided by ...
(Date:10/3/2019)... ... October 02, 2019 , ... ... sciences leadership firm that is enabling clinical program outsourcing success by cultivating radical ... award-winning pharma and biotech veteran executive Brenda Reese, phaseUP™ brings clients deep, broad ...
Breaking Biology Technology:
Cached News: